Chioncel, Ovidiu

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal

Coronary Interventions and DiagnosticsAcute Myocardial Infarction Research

Cited by 7,166

2023 ESC Guidelines for the management of acute coronary syndromes

Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 5,333

2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 4,763

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Mebazaa, A., Davison, B., Chioncel, O., Cohen-Solal, A., Diaz, R., Filippatos, G., Metra, M., Ponikowski, P., Sliwa, K., Voors, A. A., et al. (2022) · The Lancet

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 1,123

Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry

Chioncel, O., Lainscak, M., Seferovic, P. M., Anker, S. D., Crespo-Leiro, M. G., Harjola, V.-P., Parissis, J., Laroche, C., Piepoli, M. F., Fonseca, C., et al. (2017) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 927

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 893

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 879

European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions

Crespo-Leiro, M. G., Anker, S. D., Maggioni, A. P., Coats, A. J., Filippatos, G., Ruschitzka, F., Ferrari, R., Piepoli, M. F., Delgado Jimenez, J. F., Metra, M., et al. (2016) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 798

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 754

Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease—a persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V

Ferrannini, G., De Bacquer, D., De Backer, G., Kotseva, K., Mellbin, L., Wood, D., Rydén, L., collaborators, E. V., Gale, C. P., Beleslin, B., et al. (2020) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 75

Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis

Teerlink, J. R., Davison, B. A., Cotter, G., Maggioni, A. P., Sato, N., Chioncel, O., Ertl, G., Felker, G. M., Filippatos, G., Greenberg, B. H., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 41

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology

Seferović, P., Farmakis, D., Bayes-Genis, A., Ben Gal, T., Böhm, M., Chioncel, O., Ferrari, R., Filippatos, G., Hill, L., Jankowska, E., et al. (2022) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 24